A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : HRPR / high residual platelet reactivity

[Related PubMed/MEDLINE]
Total Number of Papers: 31
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   HRPR  (>> Co-occurring Abbreviation)
Long Form:   high residual platelet reactivity
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 Impact of renal function on residual platelet reactivity and clinical outcomes in patients with acute coronary syndrome treated with clopidogrel. ACS, CKD, eGFR, MACEs
2020 Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor. ACS, DAPT
2020 Effects of morphine on P2Y12 platelet inhibitors in patients with acute myocardial infarction: A meta-analysis. AMI, AUC, CI, RR, RR, SMD, TIMI
2020 Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale : The FABOLUS FASTER Trial. PCI, STEMI
2020 Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome. ACS, CI, CKD, eGFR, OR
2019 Myocardial salvage after ST-segment-elevation myocardial infarction: comparison between prasugrel and clopidogrel in the presence or absence of high-residual platelet reactivity. MSI, PPCI, SPECT, STEMI
2018 Body Mass Index and Plasma P-Selectin before Coronary Stenting Predict High Residual Platelet Reactivity at 6 Months on Dual Antiplatelet Therapy. BMI, DAPT, PCI
2018 Platelet reactivity in patients with chronic kidney disease undergoing percutaneous coronary intervention. AA, ADP, CKD, mTEG, PCI
2018 Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome. ACS, IST, OCT, PRU
10  2017 APpropriateness Assessment in Antiplatelet THerapY (APATHY) registry: Insight from current clinical practice. ACS, APATHY
11  2016 Aspirin resistance is associated with increased stroke severity and infarct volume. DWI, NIHSS
12  2016 Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: The inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial. LD, PR
13  2016 Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor. DAPT, PCI, SUA
14  2016 Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. ACS, ADP, DAPT, PCIs
15  2015 Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor. ADP, ASA, BMI, CI, DAPT, OR
16  2015 High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. ACS
17  2015 High residual platelet reactivity (HRPR) for adenosine diphosphate (ADP) stimuli is a determinant factor for long-term outcomes in acute ischemic stroke with anti-platelet agents: The meaning of HRPR after ADP might be more prominent in large atherosclerotic infarction than other subtypes of AIS. ADP, AIS, APAs, HRPA, LAA, OPA
18  2015 Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel: results from Assessing Platelet Activity in Coronary Heart Disease (APACHE). APACHE, LRPR
19  2015 Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor. ACS, ADP-antagonist, ASA, CKD, DAPT, PCI
20  2015 Predictive value of high residual platelet reactivity by flow cytometry for outcomes of ischemic stroke patients on clopidogrel therapy. ADP, AUC, CI, OR, PAG
21  2015 Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus. CTO, LRPR, PCI
22  2014 Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study. LTA, MACE
23  2014 Switching from clopidogrel to prasugrel in patients having coronary stent implantation. ---
24  2013 Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. CKD, DM, PCI
25  2013 Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. LD, PPCI, PRU, STEMI
26  2013 High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. ---
27  2013 Pharmacodynamic effect of clopidogrel in patients undergoing transcatheter aortic valve implantation. ---
28  2012 Impact of anemia on platelet response to clopidogrel in patients undergoing percutaneous coronary stenting. LTA, PCI, VN-P2Y12
29  2011 High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. ACS, PCI
30  2009 High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. DES, LRPR, ULMD
31  2009 Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. CI, OR